Cartilage Extract to Treat Lung Cancer
Name of the Trial
Why Is This Trial Important?
Like other solid tumors, NSCLC requires a constant supply of blood to grow. Drugs that block the formation of new blood vessels to tumors are called angiogenesis inhibitors. Such drugs may help cancer patients survive longer. In this trial, researchers are studying the ability of AE-941 (Neovastat), a liquid extract of shark cartilage that has angiogenesis inhibitor activity, to improve the survival of patients with unresectable NSCLC when given in combination with traditional chemotherapy and radiation therapy.
"What is different about this study is that we are using a standardized extract from cartilage instead of a drug devised from a single molecule," said Dr. Lu. "Thus, Neovastat may offer a combination of molecules that work together to inhibit angiogenesis."
"Data from animal studies support the hypothesis that this extract has antiangiogenic activity and that it may inhibit certain enzymes involved in cancer cell metastasis, such as matrix metalloproteinases 2, 9, and 12," Dr. Lu added.
Who Can Join This Trial?
Where Is This Trial Taking Place?
Who to Contact
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.